Fig. 6: Change in N stage from baseline to postdefinitive surgery in patients with stage III NSCLC and definitive surgery.
Among randomized patients with stage III NSCLC, 115 in the nivolumab arm and 111 in the placebo arm had received definitive surgery. The percentages in individual ribbons represent patients within each baseline N stage group (left) who had the indicated postsurgical N stage (right) among all patients with definitive surgery in that treatment arm. The superscript letter ‘a’ indicates that one (1%) patient in the nivolumab arm with unknown nodal stage at baseline was excluded, and postsurgical N stage was missing for three (3%) additional patients (one with cN1 at baseline and two with cN0 (no regional lymph node involvement by clinical assessment) at baseline). The superscript letter ‘b’ indicates that one (1%) patient in the placebo arm with not reported or cNX stage at baseline was excluded, and postsurgical N stage was missing for four (4%) additional patients (three with cN2 at baseline and one with cN0 at baseline).
